[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"William Stoops\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":105},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,67,86],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100610362","non-abstinence-outcomes-in-methamphetamine-use-disorder-100610362",false,"NCT07226596","Non-Abstinence Outcomes in Methamphetamine Use Disorder","Advancing Non-Abstinence Outcomes in the Treatment of Methamphetamine Use Disorder","RCT (05)","Inclusion Criteria:\n\n* be age 18 years or older;\n* self-report methamphetamine use in the week prior to screening;\n* provide a methamphetamine-positive urine sample at screening;\n* meet DSM-5 criteria for moderate-severe Methamphetamine Use Disorder (MUD);\n* be seeking treatment for their methamphetamine use\n* be able and willing to commit to the 12-week intervention, as well as the 12-week post-intervention follow-up\n* Individuals who meet these criteria and are stably maintained on buprenorphine or methadone for Opioid Use Disorder (OUD) will also be eligible to participate.\n\nExclusion Criteria:\n\n* current or past medical or psychiatric illness (e.g., physical dependence on any drug other than buprenorphine requiring medically managed detoxification, unstable angina, uncontrolled cardiac arrhythmia, aortic stenosis, self-reported compromised immune function, severe diagnosis for a SUD other than MUD or treated OUD) that would interfere with study participation in the opinion of the study physicians\n* poor venous access precluding blood draws","ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"NA","Reduced drug use is a clinically meaningful target for treatment development, but few studies have evaluated the positive impacts produced by this behavioral change, preventing adoption of this endpoint in clinical trials. The proposed research will fill that critical knowledge gap by demonstrating the biopsychosocial benefits of reduced methamphetamine use. These data will be used to change current accepted methamphetamine treatment endpoints and accelerate identification of therapies for methamphetamine use disorder.",[27],"Methamphetamine Use Disorder",[29,30,31],"methamphetamine","treatment","behavioral intervention","RECRUITING","2026-06-05",{"date":35,"type":36},"2026-06-08","ACTUAL",{"date":38,"type":36},"2026-01-14",{"date":40,"type":21},"2031-01-04",{"name":42,"class":43},"William Stoops","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":44},"100599615","early-phase-1-cocaine-and-pentoxifylline-bed-in-47-100599615","NCT07086794","Cocaine and Pentoxifylline (BED IN 47)","Targeting Immune Inflammation in Cocaine Use Disorder: A Human Laboratory Study With Pentoxifylline","Inclusion Criteria:\n\n1. able to speak\u002Fread English,\n2. not seeking treatment for drug use at the time of the study,\n3. female or male between the ages of 18 and 55 years,\n4. recent smoked or intravenous cocaine use verified by benzoylecgonine positive urine, as well as fulfillment of DSM-5 diagnostic criteria for CUD,\n5. judged to be medically and psychiatrically healthy by study physicians other than the diagnosis for CUD at the time of screening,\n6. ECG, read by a cardiologist, within normal limits,\n7. females using an effective form of birth control and not pregnant or breastfeeding and 8) no known contraindications or allergies to pentoxifylline.\n\nExclusion Criteria:\n\n1. unable to speak\u002Fread English,\n2. seeking treatment for drug use,\n3. under 18 years or over 55 years,\n4. no recent smoked or intravenous cocaine use as indicated by benzoylecgonine negative urine and no DSM-5 diagnosis of CUD,\n5. judged to be medically or psychiatrically unhealthy by study physicians at the time of screening,\n6. ECG, read by a cardiologist, outside normal limits,\n7. females not using an effective form of birth control or pregnant or breastfeeding,\n8. contraindications or allergies to pentoxifylline, and\n9. Self-reported history of head trauma, seizure, CNS tumors, or use of concomitant medications that lower seizure threshold, or first-degree family history of seizures.",true,"55 Years",{"count":55,"type":21},30,[57],"EARLY_PHASE1","This will be a human laboratory study evaluating the influence of pentoxifylline treatment on the effects of cocaine. Supported by and included in the Helping to End Addiction Long-term® (HEAL) Initiative.",[60],"Cocaine Use Disorder",{"date":35,"type":36},{"date":63,"type":36},"2025-11-10",{"date":65,"type":21},"2028-02-28",{"name":42,"class":43},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":80,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":44},"100592163","early-phase-1-methamphetamine-and-troriluzole-100592163","NCT06989853","Methamphetamine and Troriluzole","Advancing Troiluzole as a Treatment for Methamphetamine Use Disorder: A Human Laboratory Study","BED IN 46","Inclusion Criteria:\n\n1. able to speak\u002Fread English,\n2. not seeking treatment for drug use at the time of the study,\n3. female or male between the ages of 18 and 55 years,\n4. recent methamphetamine use verified by methamphetamine positive urine, as well as fulfillment of DSM-5 diagnostic criteria for MUD,\n5. judged to be medically and psychiatrically healthy by study physicians other than the diagnosis for MUD (and OUD for the co-morbid MUD and OUD group, see below) at the time of screening,\n6. ECG, read by a cardiologist, within normal limits,\n7. females using an effective form of birth control and not pregnant or breastfeeding,\n8. no known contraindications (e.g., hepatic disease \\[save for asymptomatic HCV status as cleared by study physician\\]) or allergies to troriluzole. Individuals in the MUD and OUD group must also report recent opioid use, verified by opioid positive urine, as well as fulfillment of DSM-5 diagnostic criteria for OUD with physiologic dependence (determined to not be physically dependent if a participant arrives with a urine sample for drug screening that is negative for a short-acting opioid and does not have a score of 5 or greater on the clinical opioid withdrawal scale \\[COWS\\]).\n\nExclusion Criteria:\n\n1. unable to speak\u002Fread English,\n2. seeking treatment for drug use,\n3. under 18 years or over 55 years,\n4. no recent methamphetamine use as indicated by methamphetamine negative urine and no DSM-5 diagnosis of MUD,\n5. judged to be medically and psychiatrically unhealthy by study physicians at the time of screening,\n6. ECG, read by a cardiologist, outside normal limits,\n7. females not using an effective form of birth control or pregnant or breastfeeding,\n8. blood pressure readings indicative of hypertension (i.e., blood pressure \\> 140\u002F90 mmHg) on 2 consecutive screening visits,\n9. BMI \\\u003C 18 or \\> 30; weight \\\u003C 50 kg,\n10. taking any medications prescribed by a physician for a chronic condition,\n11. any laboratory chemistry values (e.g., LFTs) \\> 3 times normal at screening or during admission,\n12. history of serious physical disease or diagnosis of any disorder (e.g., current hepatic disease \\[save for asymptomatic HCV status; as noted above\\], histories of seizure, diabetes, asthma or CNS tumors) or current or past histories of psychiatric disorder, including current or recent suicidal ideation that would limit compliance in the study, other than MUD or tobacco use disorder (and OUD for the co-morbid MUD\u002FOUD group only) that in the opinion of the study physicians would interfere with participation and\n13. contraindications (e.g., hepatic disease) or allergies to troriluzole.",{"count":76,"type":21},40,[57],"This will be a human laboratory study evaluating the influence of troriluzole treatment on the effects of methamphetamine. Supported by and included in the Helping to End Addiction Long-term® (HEAL) Initiative.",[27],{"date":35,"type":36},{"date":82,"type":36},"2025-08-25",{"date":84,"type":21},"2029-02-28",{"name":42,"class":43},{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":52,"sex":17,"minAge":93,"maxAge":53,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":99,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":44},"100541194","early-phase-1-suvorexant-and-alcohol-100541194","NCT06326684","Suvorexant and Alcohol","Influence of Orexin Antagonism on Motivation for Alcohol","Inclusion\u002FExclusion Criteria:\n\n1. Able to speak and read English.\n2. Not seeking treatment at the time of the study.\n3. Between the ages of 21 and 55 years.\n4. Engaging in at least one binge drinking episode, per the NIAAA definition, in the last 30 days.\n5. Fulfillment of moderate or severe DSM-5 diagnostic criteria for AUD based on computerized SCID results reviewed by a psychiatrist or psychologist.\n6. ECG, read by cardiologist, within normal limits.\n7. Body mass index of 19 - 35.\n8. Birthing individuals using an effective form of birth control and not pregnant or breast feeding.\n9. Judged by the medical staff to be psychiatrically and physically healthy (i.e., no current severe SUD or psychiatric diagnoses other than AUD or Tobacco Use Disorder; no current physical diagnoses that would interfere with study participation according to study physician judgment).\n10. Not currently physiologically dependent on any substances.\n11. Able to abstain from alcohol during admission (i.e., not physically dependent on alcohol and scores less than 8 on Clinical Institute Withdrawal Assessment for Alcohol \\[CIWA-Ar\\] at screening).\n12. Not currently taking any prescribed medications for a chronic condition (other than birth control).\n13. No indication of sleep apnea on the STOP-Bang questionnaire (score of 5 or greater).\n14. No contraindications\u002Fallergies to suvorexant.","21 Years",{"count":55,"type":21},[57],"This research will translate findings from preclinical research and provide the initial clinical evidence that orexin antagonism reduces motivation for alcohol, as well as other alcohol-associated maladaptive behaviors in people with Alcohol Use Disorder. This study will also provide basic science information about the orexinergic mechanisms underlying the pharmacodynamic effects of alcohol in humans. As such, the outcomes will contribute to our understanding of the clinical neurobiology of Alcohol Use Disorder. Overall, the proposed work seeks to expand the scope of current clinical neuroscience research on alcohol addiction by focusing on orexin, which has strong preclinical evidence supporting its critical role in addiction but remains unstudied in humans.",[98],"Alcohol Use Disorder",{"date":35,"type":36},{"date":101,"type":36},"2024-06-07",{"date":103,"type":21},"2027-03-15",{"name":42,"class":43},""]